Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience

TitleMucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience
Publication TypeJournal Article
Year of Publication2010
AuthorsAlexandre, J, Ray-Coquard, I, Selle, F, Floquet, A, Cottu, P, Weber, B, Falandry, C, Lebrun, D, Pujade-Lauraine, E, ,
JournalAnn Oncol
Volume21
Pagination2377-81
Keywords80 and over Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use Clinical Trials as Topic/statistics & numerical data Cystadenocarcinoma, Adenocarcinoma, Factual Disease Progression Female Humans Middle Aged Ovarian Neoplasms/*diagnosis/*drug therapy/pathology Paclitaxel/*administration & dosage/adverse effects Platinum/*administration & dosage/adverse effects Retrospective Studies Young Adult, Mucinous/*diagnosis/*drug therapy/pathology Adult Aged Aged, Mucinous/diagnosis/drug therapy/pathology Databases
Abstract

{BACKGROUND: Advanced mucinous epithelial ovarian carcinoma (mEOC) has been associated with a worse prognosis than the more common serous epithelial ovarian carcinomas (sEOC), but it remains unclear whether this observation reflects a more aggressive clinical presentation and/or chemoresistance. PATIENTS AND METHODS: Data from four randomized phase III and one phase II advanced epithelial ovarian carcinoma (EOC) first-line clinical trials were retrospectively collected, yielding 1118 patients with advanced EOC (International Federation of Gynecology and Obstetrics stages IIB-IV), 85% of whom were treated with paclitaxel (Taxol)-carboplatin-based chemotherapy. RESULTS: Based on 786 patients with sEOC and 54 (5%) with mEOC, peritoneal carcinomatosis were more limited in mEOC, which was more frequently stages IIB-IIIB (32% versus 19%